Publications by authors named "Michael D Forman"

Article Synopsis
  • PDE2A inhibitors have shown potential in improving cognitive function in preclinical models, sparking interest in their further development.
  • Researchers developed a new, highly potent PDE2A inhibitor (PF-05085727) that effectively penetrates the brain and demonstrates significant biochemical changes related to PDE2A inhibition.
  • The compound also reverses cognitive impairments caused by NMDA antagonists in rodents, suggesting it could enhance NMDA signaling and holds promise for future clinical applications in cognition.
View Article and Find Full Text PDF

We report the X-ray crystal structure of a phosphodiesterase (PDE) that includes both catalytic and regulatory domains. PDE2A (215-900) crystallized as a dimer in which each subunit had an extended organization of regulatory GAF-A and GAF-B and catalytic domains connected by long alpha-helices. The subunits cross at the GAF-B/catalytic domain linker, and each side of the dimer contains in series the GAF-A and GAF-B of one subunit and the catalytic domain of the other subunit.

View Article and Find Full Text PDF

Using SAR from two related series of pyrimidinetrione-based inhibitors, compounds with potent MMP-13 inhibition and >100-fold selectivity against other MMPs have been identified. Despite high molecular weights, clogPs, and polar surface areas, the compounds are generally well absorbed and have excellent pharmacokinetic (PK) properties when dosed as sodium salts. In a rat fibrosis model, a compound from the series displayed no fibrosis at exposures many fold greater than its MMP-13 IC50.

View Article and Find Full Text PDF